SCHEMBL5881776

SCHEMBL5881776

Cc1[nH]c2ccc(C(=O)O)cc2c1Cc1ccc(/C=C/c2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.68
POLB P06746 1/20 0.55
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 4/20 0.51
THRB P10828 1/20 0.51
HPGD P15428 1/20 0.51
PSMD14 O00487 1/20 0.50
RECQL P46063 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
APEX1 P27695 1/20 0.50
TBXAS1 P24557 1/20 0.49
PPARG P37231 1/20 0.47
MMP3 P08254 2/20 0.46
MMP7 P09237 2/20 0.46
MMP12 P39900 2/20 0.46
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPT P10636 4/20 0.43
LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5881779 1.00 PTPN5 (0.68) PTPN5POLBKDM4EALDH1A1THRB
SCHEMBL5881908 0.89 PTPN5 (0.60) PTPN5POLBKDM4EALDH1A1HPGD
SCHEMBL5881911 0.89 PTPN5 (0.60) PTPN5POLBKDM4EALDH1A1HPGD
SCHEMBL5881714 0.87 PTPN5 (0.72) PTPN5POLBKDM4EALDH1A1THRB
SCHEMBL6320931 0.85 PTPN5 (0.50) PTPN5POLBKDM4EALDH1A1THRB
SCHEMBL6319291 0.85 PTPN5 (0.50) PTPN5POLBKDM4EALDH1A1THRB
Hydroxyamine SCHEMBL5145427 0.81 PTPN5 (0.71) PTPN5POLBKDM4EALDH1A1THRB
SCHEMBL5126878 0.81 PTPN5 (0.64) PTPN5POLBKDM4EALDH1A1THRB
SCHEMBL5882137 0.81 PTPN5 (0.74) PTPN5POLBKDM4EALDH1A1THRB
SCHEMBL5881846 0.81 PTPN1 (0.46) PTPN5POLBKDM4EPSMD14RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PTPN5 2703/4885POLB 3300/4885KDM4E 2944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.